Highlights:
- Pioneering Precision: "Follow Your Heart" Integrates Health Gauge's Revolutionary EdgeAI and AI PrecisionPulse Neural Network Measurement Technology to produce a consumer wellness smartwatch solution with medical grade accuracy for blood pressure measurements.
VICTORIA, BC / ACCESSWIRE / March 6, 2024 / AI/ML Innovations Inc. (the "Company") (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB), a leading company committed to acquiring and advancing Artificial Intelligence/Machine Learning technologies that address urgent societal needs, is pleased to have received the following from its majority-owned subsidiary, Health Gauge Inc.:
Health Gauge Inc., a leading name in health tech innovation, proudly announces the commercial launch of "Follow Your Heart," a unique wellness-oriented product set to redefine how individuals monitor their blood pressure trends through the convenience of a smart watch. Combining cutting-edge technology with user-friendly design, "Follow Your Heart" leverages Health Gauge's proprietary and patented AI PrecisionPulse Neural Network measurement technology. The result is a non-invasive solution that is able to provide medical grade accuracy for blood pressure measurements and trends, through the convenience of a smartwatch. The product will be available for purchase through retail pharmacies and other channels catering to individuals managing hypertension.
According to recent statistics, nearly one half of adults in the U.S. suffer from high blood pressure, underscoring the critical need for reliable and accessible blood pressure monitoring solutions. "Follow Your Heart" emerges as a timely response to this health challenge, empowering users to take control of their cardiovascular well-being with ease.
Addressing the Hypertension Epidemic in the United States[1]
- Having hypertension puts you at risk for heart disease and stroke, which are leading causes of death in the United States.
- In 2021, hypertension was a primary or contributing cause of 691,095 deaths in the United States.
- Nearly half of adults have hypertension (48.1%, 119.9 million), defined as a systolic blood pressure greater than 130 mmHg or a diastolic blood pressure greater than 80 mmHg or are taking medication for hypertension.
- About 1 in 4 adults with hypertension have their hypertension under control (22.5%, 27.0 million).
- About half of adults (45%) with uncontrolled hypertension have a blood pressure of 140/90 mmHg or higher. This includes 37 million U.S. adults.
- About 34 million adults who are recommended to take medication may need it to be prescribed and to start taking it. Almost two out of three of this group (19 million) have a blood pressure of 140/90 mmHg or higher.
- High blood pressure costs the United States about $131 billion each year, averaged over 12 years from 2003 to 2014.
Paul Duffy, CEO of AI/ML Innovations Inc., added "We are thrilled to introduce 'Follow Your Heart,' a product that epitomizes our commitment to leveraging cutting-edge technology for the betterment of human health. In an era where health consciousness is paramount, 'Follow Your Heart' provides a user-friendly and non-invasive solution for individuals seeking precision in blood pressure trend monitoring. "Follow Your Heart" will help democratize your health and wellness by providing you, the wearer, with immediate and actionable feedback regarding your blood pressure. At AI/ML Innovations Inc., we believe in pioneering innovations that make a tangible impact on people's lives. 'Follow Your Heart' is a testament to that ethos."
###
[1]
About Health Gauge
Users can explore the features and benefits of "Follow Your Heart" by visiting the dedicated webpage:
Health Gauge, a majority-owned subsidiary of AI/ML Innovations Inc., is at the forefront of revolutionizing healthcare through the power of Health Intelligence. With a commitment to leveraging technology for human well-being, Health Gauge provides cutting-edge solutions for personalized health insights.
About AI/ML Innovations Inc.
AI/ML Innovations Inc. has realigned its business operations to capitalize on the burgeoning fields of artificial intelligence (AI) and machine learning (ML), with an initial investment focus on emerging digital health and wellbeing companies that leverage AI, ML, cloud computing and digital platforms to drive transformative healthcare management solutions and precision support delivery across the health continuum. Through strategic partnerships with Health Gauge (95.2% owned by AIML), Tech2Heal (up to 22% ownership rights, with 12.44% currently owned by AIML), AI Rx Inc. (70% owned by AIML) and other planned accretive investments, the Company continues to capitalize on expanding growth areas, to the benefit of all the Company's stakeholders. AI/ML's shares are traded on the Canadian Securities Exchange under the symbol "AIML", the OTCQB Venture Market under "AIMLF", and the Frankfurt Stock Exchange under "42FB".
On behalf of the Board of Directors
Tim Daniels, Executive Chairman
For more information about AI/ML Innovations:
For detailed information please see AI/ML's website or the Company's filed documents at
For further information, contact: Blake Fallis at (778) 405-0882 or info@aiml-innovations.com
Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
For AI/ML Innovations Investors
Certain statements made in this press release that are not based on historical information are forward-looking statements that involve substantial known and unknown risks and uncertainties. This press release contains express or implied forward-looking statements relating to, among other things, AI/ML Innovations' expectations concerning management's plans, objectives, and strategies, including strategies for defending the Company's intellectual property. These statements are neither promises nor guarantees but are subject to a variety of risks and uncertainties, many of which are beyond our control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. AI/ML Innovations Inc. undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events, or circumstances or otherwise except as expressly required by applicable securities law. Further information regarding the uncertainties and risks can be found in the disclosure documents filed by AI/ML with the securities regulatory authorities, available at .
SOURCE: AI/ML Innovations Inc.
亮點：
- 開創精度：“Follow Your Heart” 整合了Health Gauge的革命性EdgeAI和AI PrecisionPulse神經網絡測量技術，生產出具有醫療級血壓測量精度的消費類健康智能手錶解決方案。
不列顛哥倫比亞省維多利亞州/ACCESSWIRE/2024年3月6日/ AI/ML Innovations Inc.（“公司”）（CSE: AIML）（OTCQB: AIMLF）（FWB: 42FB）是一家致力於收購和推進滿足緊急社會需求的人工智能/機器學習技術的領先公司，很高興從其控股子公司Health Gauge Inc.獲得以下信息：
健康科技創新領域的領軍企業Health Gauge Inc. 自豪地宣佈商業推出 “Follow Your Heart”，這是一款以健康爲導向的獨特產品，旨在通過智能手錶的便利性重新定義個人監測血壓趨勢的方式。“Follow Your Heart” 將尖端技術與人性化設計相結合，利用了Health Gauge的專有專利AI PrecisionPulse神經網絡測量技術結果是一種非侵入性的解決方案，能夠通過智能手錶的便利性爲血壓測量和趨勢提供醫療級的準確性。該產品將可通過零售藥房和其他面向高血壓患者的渠道購買。
根據最近的統計數據，美國將近一半的成年人患有高血壓，這突顯了對可靠和易用的血壓監測解決方案的迫切需求。“Follow Your Heart” 是對這一健康挑戰的及時回應，使用戶能夠輕鬆控制自己的心血管健康。
應對美國的高血壓疫情 [1]
- 患有高血壓會使你面臨心臟病和中風的風險，而心臟病和中風是美國的主要死亡原因。
- 2021年，高血壓是美國691,095人死亡的主要或促成原因。
- 將近一半的成年人患有高血壓（48.1％，1.199億），其定義是收縮壓大於130 mmHg或舒張壓大於80 mmHg或正在服用高血壓藥物。
- 大約四分之一的高血壓成年人的高血壓得到控制（22.5％，2700萬）。
- 在患有未控制的高血壓的成年人中，約有一半（45％）的血壓爲140/90 mmHg或更高。這包括3700萬美國成年人。
- 大約有3,400萬被推薦服藥的成年人可能需要開處方才能開始服藥。該群體中幾乎有三分之二（1900萬）的血壓爲140/90 mmHg或更高。
- 高血壓每年給美國造成約1310億美元的損失，在2003年至2014年的12年中平均損失了約1310億美元。
AI/ML Innovations Inc.首席執行官保羅·達菲補充說：“我們很高興推出'Follow Your Heart '，該產品體現了我們致力於利用尖端技術改善人類健康的承諾。在健康意識至高無上的時代，“Follow Your Heart” 爲尋求精確血壓趨勢監測的個人提供了一種用戶友好且非侵入性的解決方案。“Follow Your Heart” 將通過爲佩戴者提供有關血壓的即時且切實可行的反饋，幫助您的健康和保健大衆化。在AI/ML Innovations Inc.，我們相信開創性的創新會對人們的生活產生切實的影響。'Follow Your Heart'證明了這種精神。”
###
[1]
關於生命值計
用戶可以通過訪問專用網頁來探索 “Follow Your Heart” 的特點和好處：
Health Gauge是AI/ML Innovations Inc.的多數股權子公司，站在通過健康情報的力量徹底改變醫療保健的最前沿。Health Gauge致力於利用技術促進人類福祉，爲個性化健康見解提供尖端解決方案。
關於 AI/ML Innovations Inc.
AI/ML Innovations Inc.調整了其業務運營，以利用新興的人工智能（AI）和機器學習（ML）領域，最初的投資重點是新興的數字健康和福祉公司，這些公司利用人工智能、機器學習、雲計算和數字平台推動變革性的醫療管理解決方案和整個健康連續體的精準支持交付。通過與Health Gauge（AIML持有95.2％的股權）、Tech2Heal（高達22％的所有權，目前由AIML持有12.44％的所有權）、AI Rx Inc.（AIML持有70％的股權）以及其他計劃中的增值投資，公司繼續利用不斷擴大的增長領域，使公司所有利益相關者受益。AI/ML的股票在加拿大證券交易所交易，代碼爲 “AIML”，OTCQB風險投資市場以 “AIMLF” 的形式交易，在法蘭克福證券交易所交易的代碼爲 “42FB”。
代表董事會
蒂姆·丹尼爾斯，執行主席
有關 AI/ML 創新的更多信息:
有關詳細信息，請訪問AI/ML的網站或公司提交的文件，網址爲
欲了解更多信息，請致電 (778) 405-0882 或 info@aiml-innovations.com 與 Blake Fallis 聯繫
CSE及其監管服務提供商（該術語在CSE的政策中定義）均不對本新聞稿的充分性或準確性承擔責任。
致人工智能/機器學習創新投資者
本新聞稿中發表的某些非基於歷史信息的陳述是前瞻性陳述，涉及大量已知和未知的風險和不確定性。本新聞稿包含與AI/ML Innovations對管理層計劃、目標和戰略（包括捍衛公司知識產權的戰略）的預期有關的明示或暗示的前瞻性陳述。這些陳述既不是承諾也不是擔保，但存在各種風險和不確定性，其中許多風險和不確定性是我們無法控制的，這可能導致實際結果與這些前瞻性陳述中設想的結果存在重大差異。提醒現有和潛在投資者不要過分依賴這些前瞻性陳述，這些陳述僅代表截至本文發佈之日。除非適用的證券法明確要求，否則AI/ML Innovations Inc. 沒有義務更新或修改本新聞稿中包含的信息，無論是由於新信息、未來事件或情況還是其他原因。有關不確定性和風險的更多信息，可以在AI/ML向證券監管機構提交的披露文件中找到，網址爲。
來源：AI/ML Innovations Inc.
